

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 April 2005 (28.04.2005)

PCT

(10) International Publication Number
WO 2005/037083 A3

(51) International Patent Classification⁷: **G01N 33/534**,
C12Q 1/68

(74) Agent: LAUDER, Leona, L.; Suite 1026, 235 Mont-
gomery Street, San Francisco, CA 94104-3008 (US).

(21) International Application Number:
PCT/US2004/034573

(22) International Filing Date: 18 October 2004 (18.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/511,832 16 October 2003 (16.10.2003) US

(71) Applicant (for AM, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG only): BAYER HEALTH-
CARE [US/US]; Diagnostic Business Group, 511 Benedict
Avenue, Tarrytown, NY 10591-5097 (US).

(71) Applicant (for all designated States except US): INSTI-
TUTE OF VIROLOGY [SK/SK]; Slovak Academy of
Sciences, Dubravska Cesta 9, 842 46 Bratislava (SK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): EBERT, Matthias
[DE/DE]; Lentkestrasse 57, 39116 Magdeburg (DE).
ROCKEN, Christoph [DE/DE]; Brunnerstrasse 24, 39112
Magdeburg (DE). PASTOREKOVA, Silvia [SK/SK];
Novoveska 18, 841 07 Bratislava (SK). ZAVADA, Jan
[CZ/CZ]; Na pekne vyhlidce 1, 162 00 Prague (CZ).
PASTOREK, Jaromir [SK/SK]; Novoveska 18, 841 07
Bratislava (SK).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
24 November 2005

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: MN/CA IX AND CANCER PROGNOSIS

(57) Abstract: Herein disclosed are methods that are prognostic for neoplastic/preneoplastic disease in a subject vertebrate, wherein said disease is associated with a tissue that normally expresses MN, but which MN expression is lost or diminished upon carcinogenesis. Exemplary of the types of preneoplastic/neoplastic diseases subject to the prognostic methods of this invention are those of gastric mucosa, gallbladder, biliary ducts, and ductal cells of duodenal glands. An exemplary prognostic method comprises comparing the level of MN gene expression product in a tissue sample from the affected subject, with the average MN gene expression product level found in analogous preneoplastic/neoplastic tissue samples; an above average MN gene expression product level indicates poorer prognosis for the subject. MN gene expression products useful in the prognostic methods include MN protein, MN polypeptide, and/or MN nucleic acids.



WO 2005/037083 A3